INTRODUCTION
RNA interference (RNAi)-mediated silencing of human immunodeficiency virus type 1 (HIV-1) replication can be achieved by transfection of short interfering RNA (siRNA) or DNA vectors containing siRNA expression cassettes. Recent work has demonstrated that cellular expression of siRNA targeting HIV-1 proteins such as tat, rev, and gag inhibits virus replication, raising the possibility of using RNAi as a genetic therapy for chronic HIV-1 infection [1 -7] . Application of antiviral RNAi in a clinical setting will require the use of efficient vector delivery systems capable of mediating long-term, stable siRNA expression.
Recombinant adeno-associated virus (rAAV) is an attractive vehicle for gene therapy that offers several advantages over other vector systems of viral origin. A major safety concern of retroviral vectors is the insertional activation of cellular proto-oncogenes resulting from random integration of provirus into the host genome. One of the most attractive features of AAV is its ability to integrate site-specifically into the AAVS1 region of chromosome 19, thereby reducing the mutagenic and carcinogenic potential of somatic gene transfer [8 -11] .
Due to the requirement of helper virus for productive infection, adeno-associated viruses are naturally replication-deficient parvoviruses and have not been associated with any human disease [12] . Moreover, AAV-2 exhibits a broad host range and infects a wide variety of tissues and cells [13 -17] . AAV-2-derived viral vectors have been used successfully for efficient long-term gene expression in both dividing and nondividing cells [13 -16] . As opposed to retroviral vectors, recombinant AAV vectors are devoid of endogenous promoters, thereby excluding the possibility of promoter interference between an upstream viral promoter (e.g., LTR) and an internal promoter of an expressed transgene [17, 18] .
Given previous demonstration of AAV-mediated delivery of therapeutic RNA molecules such as ribozymes [19, 20] , we sought to determine the utility of AAV-2 for the stable genetic transfer of short hairpin RNA (shRNA) expression cassettes into a lymphocytic cell line and primary human lymphocytes. Employing this system, we tested the antiviral activity of shRNA that targets the HIV-1 transactivator protein tat.
RESULTS AND DISCUSSION
Antiviral Activity of a tat shRNA Expression Construct We introduced the shRNA expression cassette into a recombinant AAV DNA vector. The cassette consisted of an upstream MTD (modified-tRNA-derived) Pol III-type promoter followed by a short hairpin DNA sense and antisense sequence, separated by a hexaloop (Fig. 1) . We chose the MTD promoter given the recent demonstration that it more effectively mediates HIV-1-specific RNAi compared to other Pol III promoters such as U6, U6+1, and H1 [21] . We determined the tat shRNA target sequence by alignments of computer-predicted secondary structures (mfold 2.0) of HIV-1 tat exon 1. We selected the five lowest free energy structures for the analysis and scanned 21-to 23-nt sequence stretches that were conserved among all energy structures for potential siRNA target sites. The resulting construct pAAV-tat contained a 22-nt target sequence with favorable predicted secondary structure features such as free energy (DG) of the target site, total numbers of unpaired nucleotides, and major loop size. We constructed a control vector (pAAV-luc) by introducing luciferase-specific sequences into the shRNA expression construct.
To assess the antiviral potency of the tat shRNA expression vector, we cotransfected 293T cells with pAAVtat or control vector pAAV-luc and the infectious molecular clone HIV-1 NL4. 3 . We collected cell-free supernatant 2 days after transfection and quantified HIV-1 p24 antigen levels by ELISA. HIV-1 production was reduced by 72-fold in cells transfected with pAAV-tat compared to pAAV-luc control vector.
Generation of Cell Lines Stably Expressing shRNA and HIV-1 Challenge
We produced infectious rAAV particles with an AAV helper-free system that consisted of cloning, packaging, and helper vectors. The AAV cloning vector contained the Pol III-driven shRNA expression cassettes and farther downstream a Pol II promoter-driven neomycin resistance gene or GFP reporter gene. Infectious particles were generated after cotransfection of 293T cells with equimolar amounts of AAV cloning, packaging, and helper vectors. We chose H9 cells, which are highly permissive for HIV-1 infection, for the AAV transduction. The cells were preincubated with DNA synthesis inhibitors based on previous reports that AAV transduction of cells is enhanced by chemical induction using certain DNAdamaging agents [22] . We determined the transduction efficiency of this method using rAAV-hrGFP and it revealed consistent transduction efficiencies of about 30%, determined by flow cytometry for GFP expression. Finally, we transduced H9 cells with rAAV-tat and rAAVluc, which contain in addition to the shRNA expression cassette the neomycin drug resistance gene, and placed them under drug selection for 4 weeks.
Verification of Genomic Integration of rAAV
Previous work has revealed that the most common integration site of AAV into the host genome is at AAVS1, which is located on human chromosome 19 within 19q13.4 [8, 23, 24] . To verify rAAV-2 genomic integration, we performed an AAVS1-specific AAV PCR as previously described by Huser et al. [10] and verified the results by Southern blot analysis. We subjected DNA extracted from rAAV-2-transduced and neomycin-selected H9 cells to a two-step AAVS1 AAV PCR ( Fig. 2A) . The first-step PCR includes the pAAV-tat-specific forward primer PAV-s and the reverse primer PAAVS1-as, which is complementary to a region in the AAVS1 gene of chromosome 19. The second-step PCR consists of two AAV-specific primers. As shown in Fig. 2B , integration of rAAV-tat was demonstrated in the genomic DNA of stably transduced H9 cells compared to the appropriate controls. We included, minus-first-step PCR sample (Fig. 2B , lane 5) to rule out contamination and/or coamplification of episomal rAAV in the second-step PCR.
To verify these findings, we performed a Southern blot on DNA isolated from rAAV-2-transduced and neomycinselected H9 cells. The Southern blot shows genomic integration of recombinant AAV-2 (Fig. 2C) . The two bands observed in the EcoRV lane may indicate two different integration events within AAVS1. It is known that AAV can integrate in various positions in the 4-kblong AAVS1 site [10] . One EcoRV site is present within the AAVS1 site and two additional EcoRV sites are located approximately 5.4 kb upstream and 5.8 kb downstream of AAVS1. It is conceivable that one integration event leaves the internal AAVS1 EcoRV site intact, while the other integration event removes the EcoRV site. AAV integration events can lead to disruption, deletions, and rearrangements of the AAVS1 target [25, 26] with chromosomal deletions up to 2 kb [26] . Thus, the potential removal of the EcoRV site within AAVS1 combined with different degrees of chromosomal deletions may explain the observed two bands indicating two separate integration events.
Quantification of tat shRNA Expression in Stably Transduced Cell Lines
We quantified precursor tat shRNA expression levels in transduced H9 cells by real-time PCR over a 21-day period. The MTD promoter belongs to the class II polymerase III promoters that are intragenic and cotranscribed with the tat shRNA. The total length of the resulting transcript including the shRNA is 150 bp and can therefore be readily detected by RT-PCR. We subjected total RNA to reverse transcription and real-time PCR. Input RNA amount was normalized by GAPDH PCR. Fig. 3 shows the expression of MTD tat shRNA transcripts in transduced and neomycin-selected cells at different time points after HIV-1 infection. The results demonstrate stable expression of tat-specific shRNA transcripts up to day 21 of viral infection, corresponding to day 48 posttransduction with rAAV-tat.
HIV-1 Challenge of Transduced H9 Cells and Primary Lymphocytes
We infected H9 cells permanently expressing tat or luc shRNA with 100 TCID 50 of HIV-1 NL4-3 . We assayed culture supernatant for p24 antigen production over a 3-week period. On day 21 HIV-1 replication was suppressed by 1200-fold in cultures of H9 cells expressing tat shRNA, compared to cultures of cells expressing luc shRNA (Fig. 4A) . Northern blot analysis of total intracellular HIV-1 RNA confirmed the p24 antigen results with specific degradation of full-length HIV-1 RNA in infected H9 cells expressing tat shRNA compared to control cells expressing luc shRNA on day 21 postinfection (Fig. 4B) .
Next, we assessed whether AAV could be used to transfer HIV-1-specific RNAi to primary lymphocytes.
We obtained peripheral blood mononuclear cells of an anonymous HIV-1 seronegative donor from the Rhode Island Blood Bank and depleted them of CD8 + T lymphocytes using magnetic beads (Dynal, NY, USA). We transduced the resulting CD4 + T lymphocyte-enriched population with AAV-tat and AAV-luc. For these experiments, the neomycin resistance gene was replaced with blasticidin to allow for rapid selection of transduced cells. After 1 week of drug selection in blasticidin (1 Ag/ ml), we placed the CD4 + T lymphocytes in medium containing IL-2 (10 U/ml) and PHA (2 Ag/ml) and challenged them with 1000 TCID 50 (50% tissue culture infectious dose) of HIV-1 NL4-3 . Measurement of p24 antigen level in culture supernatant 3 days after viral challenge revealed a 21-fold reduction of HIV-1 replication in CD4 + T lymphocytes expressing tat shRNA compared to cells expressing luc shRNA. This degree of inhibition is comparable to that of recent studies employing lentiviral delivery of si/shRNA expression cassettes targeting both HIV-1 gene products and accessory cellular proteins required for the viral life cycle (e.g., the CCR5 coreceptor) [27, 28] .
RNA interference offers a powerful technique to inhibit selectively the expression of disease-related genes such as oncogenes [29] . RNAi can inhibit the replication of viruses such as HIV-1, hepatitis C, and human papillomavirus [30 -32] . Thus far, permanent expression of siRNA has been most frequently achieved by the use of retroviral delivery systems [33] . Recent work has demonstrated that lentiviral constructs are able to engineer RNAi in primary lymphocytes and stem cells [27, 34] . Although these systems allow successful transduction of a wide variety of cell types, their application to human diseases may be limited given the possibility of insertional activation of cellular oncogenes by random integration of retrovirus into the host genome, as recently observed in a gene therapy trial for human severe combined immunodeficiency-X1 disease [35, 36] .
Our results demonstrate the utility of rAAV-2 in attaining stable expression of HIV-1-specific shRNA in human lymphocytic cells and primary lymphocytes. Despite the availability of highly active antiretroviral therapy, the dynamic replication kinetics of HIV-1 ensures the eventual selection of viral species that escape drug and immune control. Nearly 50% of individuals who initiate highly active antiretroviral therapy will eventually fail treatment due to the emergence of drug-resistant virus. Currently, individuals who harbor multidrug-resistant HIV-1 have few therapeutic options. In the absence of new, effective antiviral agents, these patients will eventually progress to severe immunodeficiency and death. Control of HIV-1 replication by genetic transfer of HIV-1-specific shRNA to stem cells or lymphocytes ex vivo may be an option for these individuals to delay progression to AIDS. It is not yet known whether HIV-1-specific RNAi can durably suppress virus replication in a clinical setting. It is likely that the 20-fold inhibitory effect we observed in primary lymphocytes expressing tat shRNA in vitro will be insufficient to contain HIV-1 replication in vivo. Thus, an important research goal must be to devise more potent HIV-1-specific shRNA constructs. Several aspects of the RNAi machinery could potentially be manipulated to increase the efficiency of the resulting gene silencing. For example, it has been demonstrated that the choice of Pol III promoter impacts directly the potency of HIV-1-specific RNAi [21] . Alternatively, it may be possible to design vectors capable of delivering multiple shRNAs simultaneously and thus achieve a synergistic or additive effect. Further investigations are warranted regarding the optimization of HIV-1 RNAi and the clinical potential of rAAV-mediated genetic transfer of si/shRNA expression cassettes into human cells.
METHODS
Construction of MTD promoter-driven shRNA expression cassette. The MTD promoter was generated by recombinational PCR using the following primers: TS, 5V-TGCTGGGCCCATAACCCAGAGGTCGATGGATC-GAAACCTGCGCCACTCCTGATGAGCCTCTAGACACTCTCGAGGGC-GAT-3V; TAS, 5V-ATCGCCCTCGAGAGTGTCTAGAGGCTCATCAGGA-GTGGCGCAGGTTTCGATCCATCGACCTCTGGGTTATGGGCCCAGCA-3V; Not-TS, 5V-GCGGCCGCGGCAGAACAGTCGAGTGGCGCAGCG-GAAGCGTGCTGGGCCCATAAC-3V, and Not-TAS, 5V-GCGGCCGCATC-GATGTTAGGAGATCTAAACAGAACAGTATCGCCCTCGAGAGTGTC-TAG-3V. The resulting PCR product was cloned into the NotI site of the shuttle vector pCMV-MCS (Stratagene, Valencia, CA, USA), yielding the construct pCMV-MTD-MCS. For the production of stable cell lines, a neomycin resistance cassette, including the SV40 early promoter and the SV40 polyadenylation signal, was inserted into the BglII and ClaI sites of pCMV-MTD-MCS construct. To determine transfection efficiency of the producer cell line and transducing viral titers, humanized Renilla reniformis green fluorescent protein was introduced into the above restriction sites. The resulting shRNA expression cassettes were subcloned into the NotI site of pAAV-MCS (Stratagene). To incorporate the target shRNA sequence, two complementary DNA oligos were synthesized, annealed, and inserted between the XbaI and the XhoI sites within the MTD promoter of pAAV-MTD-Neo. The DNA oligo sequences consisted of 21-nt sense and reverse complementary sequences separated by a 6-nt loop and terminated by a five-thymidine termination signal. The resulting forward sequence of shRNA of pAAV-tat was 5V-CTGCTTGTACCAATTGC-TATTAGGATCAATAGCAATTGGTACAAGCAGTTTTT-3V. The 6-nt loop is highlighted in bold. A control vector, pAAV-luc, was constructed targeting the luciferase protein of the firefly Photinus pyralis with the luc shRNA sequence 5V-AATGTCCGTTCGGTTGGCAGAAGGATCTCTGCCAACC-GAACGGACATTTTT-3V. All shRNA expression cassettes were sequence verified.
Cell transfections. 293T cells were cotransfected with pAAV-tat or pAAVluc (1 Ag) and 1 Ag HIV-1 NL4.3 using 6 Al Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) per reaction. Twenty-four hours prior to transfection, cells were trypsinized and plated at 4 Â 10 5 cells per well in six-well plates in DMEM containing 10% fetal bovine serum (FBS).
Creation of recombinant AAV for the genetic delivery of shRNA expression cassettes. To create cell lines permanently expressing tat and luc shRNA, we used an AAV Helper-Free System (Stratagene), which consists of a pAAV cloning vector and pAAV-RC packaging and pAAVhelper vectors. The pAAV cloning vector contains a CMV-promoterdriven expression cassette with a multiple cloning site for the introduction of the gene of interest flanked by inverted terminal repeats (ITRs), which are essential for chromosomal integration of AAV-2. The AAV-RC vector encodes rep and cap DNA replication proteins necessary for the production of infectious virus. The AAV helper plasmid contains the adenovirus genes E2A and E4, which are critical for virus particle production. The 293T cell line stably expresses adenovirus E1A and E1B proteins, which are essential for packaging recombinant virions. Replication-deficient, infective recombinant viral particles are produced upon cotransfection of the three DNA vectors in 293T cells. The AAV cloning vector was modified by removing the expression cassette flanked by the ITR and replacing it with the tat shRNA and luc shRNA expression cassettes including the neomycin/blasticidin drug selection marker or the GFP reporter gene. 293T cells were plated at a concentration of 5Â10 5 in 2 ml DMEM containing 10% FBS in six-well plates 24 h prior to transfection. Each plasmid (recombinant pAAV expression plasmid, pAAV-RC, and pAAV-Helper; 1.5 Ag was combined, precipitated, and eluted in 20 Al of elution buffer. The combined DNA was transfected into 293T cells using 15 Al Lipofectamine 2000. Cells were harvested 72 h posttransfection and subjected to four rounds of freeze/thaw in dry ice -ethanol and a 37jC water bath, respectively. Cells were spun down at 5000g for 10 min at 4jC and the supernatant was filtered and stored at À80jC. Viral titers of recombinant AAV were determined 48 h postinfection of H9 cells by flow cytometry using the pAAV-hrGFP expression vector.
It has been previously shown that AAV vectors transduce S-phase cells at >200 times the frequency of non-S-phase cells [22] . Treatment of non-Sphase or S-phase cells with various DNA-damaging agents increased AAV transduction frequencies up to 750-fold [22, 37] . Therefore, we chemically induced H9 cells and CD8 + -depleted primary lymphocytes with the DNA synthesis inhibitors hydroxyurea (100 mM) and sodium butyrate (3 mM) for 6 h at 37jC. Cells were washed and resuspended in 500 Al RPMI containing 5 Ag/ml Polybrene and infected at a M.O.I. of 0.3 with either rAAV-tat or rAAV-luc. Viral transduction was performed at 37jC for 2 h. Two days later, cells were washed and resuspended in RPMI containing 600 Ag/ml neomycin and maintained for 6 weeks. The chemical induction method combined with the addition of Polybrene gave consistent transduction efficiencies of about 30% determined by flow cytometry for GFP expression.
Genomic integration of rAAV. To verify recombinant AAV-2 genomic integration, we performed AAVS1-specific AAV PCR and Southern blot analysis. DNA from rAAV-2-transduced and neomycin-selected H9 cells was extracted from 1 Â 10 7 cells using the QIAamp DNA kit (Qiagen, Valencia, CA, USA). Genomic DNA (500 ng) was subjected to a two-step AAVS1 AAV PCR (Fig. 2A) . The first-step PCR includes the pAAV-tatspecific forward primer PAV-s, 5V-CTAACTGACACACATTCCAC-3V, and the reverse primer PAAVS1-as, 5V-GATCCGCTCAGAGGACATCAC-3V, which is complementary to a region in the AAVS1 gene of chromosome 19. The PCR was carried out for 30 cycles (98jC for 20 s/56jC for 30 s/ 72jC for 5 min) using LA-Takara polymerase (Panvera -Invitrogen, Madison, WI, USA) according to the supplier's instructions. One microliter of the first-step PCR product was used as template in the seminested second-step PCR, which contained two pAAV-tat-specific primers, PAVs (same as above) and PAV-as, 5V-CATAACCCAGAGGTCGATG-3V. The second-step PCR was performed under Titanium Taq polymerase (Clontech) under the following thermal cycling conditions: 95jC for 1 min and 25 Â (95jC for 15 s, 55jC for 30 s, 68jC for 30 s). Southern blot analysis was performed on 6 Ag of genomic DNA, which was digested with HindIII or EcoRV (absent restriction sites in pAAV-tat) and separated on a 0.8% agarose gel. The gel was denatured, neutralized, and then blotted in 20Â SSC transfer buffer on a Zeta-Probe GT membrane (BioRad, Hercules, CA, USA). The membrane was probed with a 400-bp neomycin-specific DNA probe, which was 32 P-labeled using the Megaprime DNA labeling system (Amersham Biosciences, Piscataway, NJ, USA). Hybridization was carried out at 65jC in Ultrahyb Buffer (Ambion) and membranes were washed twice in 2Â SSC, 0.1% SDS and 0.2Â SSC, 0.1% SDS at 65jC. Quantification of precursor shRNA expression level. Precursor tat shRNA expression levels in transduced H9 cells were assayed by real-time PCR over a 21-day period. Total cellular RNA was isolated by Trizol (Invitrogen) extraction and treated with RQ1 DNase (Promega, Madison, WI, USA) according to the manufacturer's protocol. One microgram of DNase I-treated RNA was used for the RT reaction using Powerscript Reverse Transcriptase (Clontech, Palo Alto, CA, USA) following the supplier's recommended usage. One microliter of cDNA was added to the PCR mix including 1Â Titanium Taq PCR buffer (Clontech); 20 pmol of sense primer MT-S, 5V-GGCAGAACAGTCGAGTG-3V, and antisense primer MT-AS, 5V-CAATTGGTACAAGCAGTTCTAGAG-3V; 1 mM dNTPs; SYBR Green I (1:75,000); 10 nM fluorescein, and 1Â Titanium Taq polymerase (Clontech). RNA normalization was performed by GAPDH PCR with the primers G1, 5V-GATTTCTCCCCCTTCTGCTGATG-3V, and G2, 5V-CCTTGGCTGGGGGTGCTAA-3V. Real-time PCR was carried out in an iCycler (Bio-Rad) using the following thermal cycling profile: 95jC for 1 min and 35 Â (95jC for 15 s, 61jC for 30 s, 68jC for 30 s) .
HIV-1 infection of transduced target cells. Two million 293T cells were preplated on 10-cm dishes in DMEM supplemented with 10% FBS. After 24 h 10 Ag of the molecular infectious clone HIV-1 NL4.3 was transfected into preplated 293T cells using Lipofectamine 2000. Forty-eight hours later viral supernatant was harvested, spun down to remove any remaining cells, and filtered through a 0.45-Am syringe filter. Ten million H9 cells were infected with 1 ml of viral supernatant for 2 h at 37jC. Cells were washed twice in PBS, resuspended in 10 ml complete RPMI, and maintained in culture for 14 days. Culture supernatant was collected on day 14 postinfection, spun down, filtered through a 0.45-Am syringe filter, and stored frozen at À70jC for later use. The resulting viral stocks were titered on PHA-stimulated PBMCs and H9 cells and the TCID 50 was determined by the method of Reed and Muench. Five million H9 cells transduced with MTD-luc and MTD-tat, respectively, were infected with 100 TCID 50 of viral stock for 2 h at 37jC, washed twice with PBS, and resuspended in 5 ml cRPMI (10% FBS, penicillin 100 U/ml, streptomycin 100 Ag/ml) supplemented with 600 Ag/ml neomycin. Five hundred thousand CD8
+ -depleted and PHA-stimulated peripheral blood lymphocytes transduced with MTD-luc or MTD-tat were infected with 1000 TCID 50 of viral stock as described above for H9 cells. Cells were resupended in cRPMI containing IL-2 (10 U/ml), PHA (2 Ag/ml), and blasticidin (1 Ag/ml).
Northern blot for intracellular HIV-1 RNA. Total cellular RNA was extracted from rAAV-tat/luc-transduced H9 cells 21 days after infection with HIV-1 NL4.3 . Ten micrograms of total cellular RNA was incubated in glyoxal sample loading dye (Ambion) for 1 h at 50jC, separated on a 1.2% agarose gel, and transferred to a nylon membrane using the Turboblotter system (Schleicher & Schuell, Dassel, Germany). RNA was blotted on a Zeta-Probe GT membrane (Bio-Rad) and immobilized by UV crosslinking. HIV-1 RNA was detected with a 32 P-random-labeled gag DNA probe (HIV-1 NL4.3 position 1631 -2130). Hybridizations were carried out at 65jC using Ultrahyb-Oligo hybridization buffer (Ambion). The membranes were washed twice in 2Â SSC, 0.1% SDS and 0.2Â SSC, 0.1% SDS at 60jC. As an internal standard, a 500-bp 32 P-random-labeled GAPDH DNA probe was used. Filters were stripped between hybridizations by incubation in 0.1Â SCC, 0.71% SDS at 95jC.
